Aptorum Group Limited Class A Ordinary Shares
Veridion Score
Composite trend over time
Why is APM moving today?
Aptorum Group Ltd is a clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Aptorum's project pipeline includes SACT-1, a repurposed drug for the treatment of neuroblastoma, and ALS-4, a small molecule for the treatment of bacterial infections caused by Staphylococcus aureus, including but not limited to Methicillin-resistant Staphylococcus aureus (MRSA). Substantially all of the company's revenues are derived from within Hong Kong.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for APM.
APM insider activity
Aptorum Group Limited Class A Ordinary Shares
No multi-insider buying cluster in the last 90 days
Mixed: Not disclosed across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
The current Form 4 feed did not return value-bearing open-market rows for APM.
APM contract awards, year to date.
Public federal awards linked to this ticker.
APM lobbying filings, year to date.
Registered lobbying filings matched to Aptorum Group Limited Class A Ordinary Shares.